Agreed, in terms of the company viability, there is now less urgency to get an early close to the trial thanks to NVS.
Viability's not the right word, but hopefully readers will know what I mean.
In terms of terms of covid-19, the urgency is growing. Over to you NIH, DSMB, FDA or whoever you are.
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-383
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $6.040M | 3.735M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 12184 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 7147 | 13 |
View Market Depth
| Last trade - 15.08pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |